Currently, there are 46.25M common shares owned by the public and among those 35.25M shares have been available to trade.
The company’s stock has a 5-day price change of -3.90% and 4.58% over the past three months. JANX shares are trading 276.51% year to date (YTD), with the 12-month market performance up to 221.40% higher. It has a 12-month low price of $5.65 and touched a high of $65.60 over the same period. JANX has an average intraday trading volume of 815.63K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.75%, -17.52%, and 71.31% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Janux Therapeutics Inc (NASDAQ: JANX) shares accounts for 73.03% of the company’s 46.25M shares outstanding.
It has a market capitalization of $2.09B and a beta (3y monthly) value of 3.55. The earnings-per-share (ttm) stands at -$1.22. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.52% over the week and 6.39% over the month.
Earnings per share for the fiscal year are expected to increase by 3.62%, and -24.45% over the next financial year.
Looking at the support for the JANX, a number of firms have released research notes about the stock. Scotiabank stated their Sector Perform rating for the stock in a research note on May 30, 2024, with the firm’s price target at $47. BTIG Research coverage for the Janux Therapeutics Inc (JANX) stock in a research note released on March 21, 2024 offered a Buy rating with a price target of $62. Cantor Fitzgerald was of a view on March 20, 2024 that the stock is Overweight, while Wedbush gave the stock Outperform rating on April 06, 2023, issuing a price target of $24. William Blair on their part issued Outperform rating on November 14, 2022.
